What are the Therapeutic Approaches Targeting Cyclins and CDKs?
Given their pivotal role in cancer, cyclins and CDKs are attractive therapeutic targets. Several strategies have been developed to inhibit their function:
CDK inhibitors: Small molecule inhibitors such as Palbociclib, Ribociclib, and Abemaciclib specifically inhibit CDK4/6 and are approved for treating HR-positive, HER2-negative breast cancer. RNA interference (RNAi): Targeting mRNA of specific cyclins or CDKs using siRNA or shRNA can downregulate their expression. Monoclonal antibodies: These can be designed to target and degrade overexpressed cyclins.
